FSHR and ovarian carcinoma: The findings in this study agree with previous studies demonstrating decreased FSHR mRNA and FSHR protein expression with increasing clinical stage and progression from borderline tumors to ovarian carcinomas [22] and higher FSHR expression in low grade tumors compared to grade III tumors [15,16].